Multiple myeloma drug carfilzomib added to PBS

A NEW cancer drug that could drastically extend the life of up to 1700 Australians a year waiting for a cure will be made available at a fraction of the cost from Monday.

A NEW cancer drug that could drastically extend the life of up to 1700 Australians a year waiting for a cure will be made available at a fraction of the cost from Monday.

The groundbreaking treatment for multiple myeloma — a cancer of plasma cells — is among a string of new cancer treatments added to the Pharmaceutical Benefits Scheme from January 1.

HAMISH MCLACHLAN: WHY PROFESSOR MILES PRINCE WANTS TO GET RID OF CHEMOTHERAPY

VICTORIAN RESEARCHERS AWARDED $270M TO DEVELOP NEXT GENERATION BREAKTHROUGHS

Around 550 patients are expected to immediately benefit each year from the subsidised carfilzomib, marketed under the name Kyprolis, which works by reducing the growth of cancer cells and helps boost survival rates for patients.

Normally patients would pay around $138,800 per course of treatment — but the change means they will now pay a maximum of $39.50 for each script, with concessional patients paying just $6.40.

The disease can prevent healthy plasma cells from working the way they should, making the bones weaker and leading to the spread of tumours in the bones.

A cancer drug that could drastically extend the life of up to 1700 Australians a year waiting for a cure will be made available at a fraction of the cost from Monday. Generic picture: iStock

Of the 1700 Australians who are diagnosed with myeloma each year, almost all are older than 40 years.

It is most common in people aged 60 and older.

Gary Floyd, a 71-year-old sufferer of multiple myeloma, said the treatment had changed his life. He said it “filled him with joy and hope”.

Myeloma Australia chief executive Steve Roach said the move would bring “great hope” to sufferers. Since multiple myeloma did not have a cure, most patients would relapse.

“Everyone lives in hope for a cure, but this treatment is what’s keeping that hope alive for many people by extending their lives,” Mr Roach told the Herald Sun.

“There are people who have mortgaged their homes, dipped into their superannuation or life savings just to access this treatment.”

Federal Health Minister Greg Hunt will also on Saturday announce the listing of alectinib, known as Alecensa, among the $300 million for new life-changing medicines.

About 250 eligible patients suffering from anaplastic lymphoma kinase-positive non-small cell lung cancer will be able to access the drug.

About 330 sufferers of cystic fibrosis will also be about to ­access mannitol, which trades under Bronchitol, having previously paid around $4340 a year.

“For many Australians these medications would have been out of reach until now,” Mr Hunt said. “Since coming into government, the Coalition has added $7.7 billion worth of medicines to the PBS.”

[e-mail]